NCT01104480撤回2 期
Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- Efficacy of Tocilizumab
研究概览
简要总结
This is a study for one patient with severe relapsing polychondritis which has been unresponsive to other more conventional medications including prednisone, methotrexate, anakinra and TNF inhibitors. Tolerability, and efficacy of the drug, Tocilizumab will be monitored by clinical assessment and bloodwork.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 15 Years（Child）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •A single patient with unremitting inflammatory relapsing polychondritis
排除标准
- •As this is a study in a single patient, there are no exclusions
结局指标
主要结局
Efficacy of Tocilizumab
时间窗: 2 years
Inhibition of inflammatory markers Improvement in symptoms and signs
次要结局
- Safety of Tocilizumab(2 years)
研究者
Dr Maggie Larche
Associate professor
McMaster Children's Hospital
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Single Patient Study to Treat Relapsing Polychondritis With TocilizumabRelapsing PolychondritisNCT01041248Children's Hospital of Eastern Ontario1
已完成
2 期
Tocilizumab in the Treatment of Refractory Polymyositis and DermatomyositisPolymyositisDermatomyositisNCT02043548Chester Oddis36
已完成
不适用
Success of tocilizumab in RA patients with remission induction and sustained efficacy after discontinuatiorheumatoid arthritisJPRN-UMIN000002744Keio University300
进行中（未招募）
1 期
TOCIlizumab for difficult-to-treat RETroperitoneal fibrosis. TOCIRET Trial”idiopathic retroperitoneal fibrosisMedDRA version: 20.1Level: LLTClassification code 10021244Term: Idiopathic retroperitoneal fibrosisSystem Organ Class: 100000004856EUCTR2017-001429-41-ITAZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA18
已完成
不适用
Tocilizumab treatment of cyclophosphamide-resistant patients with ANCA-associated vasculitisANCA-associated vasculitisJPRN-UMIN000002892Research Committee of multicentre clinical trials for intractable ANCA-associated vasculitis of the Ministry of Health, Labor and Welfare of Japan5